ACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
24 August 2016 - 6:40AM
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system disorders, today announced that the underwriters for
the Company’s previously announced public offering have fully
exercised their option to purchase an additional 909,090 shares.
All 6,969,696 shares sold in the offering were offered by ACADIA at
a price to the public of $33.00 per share, for total gross proceeds
to ACADIA of approximately $230.0 million before deducting
underwriting discounts and commissions and other offering expenses
payable by ACADIA. The closing of the sale of 6,060,606 shares was
completed on August 15, 2016, and the closing of the sale of
909,090 shares pursuant to the full exercise by the underwriters of
their option to purchase additional shares was completed earlier
today.
J.P. Morgan Securities LLC, Goldman, Sachs & Co. and BofA
Merrill Lynch acted as the joint book-running managers for the
offering. Cowen and Company, LLC, Piper Jaffray & Co. and
Needham & Company, LLC acted as co-managers for the
offering.
The shares of common stock described above were offered by
ACADIA pursuant to a shelf registration statement filed by ACADIA
with the Securities and Exchange Commission (SEC) that became
automatically effective on March 3, 2014. A final prospectus
supplement and accompanying prospectus relating to the offering
have been filed with the SEC and are available on the SEC’s website
located at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus related to this offering
may be obtained from J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at (866) 803-9204, or by email to:
prospectus-eq_fi@jpmchase.com, or from Goldman, Sachs & Co.,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, or by telephone at (866) 471-2526, or by email to:
prospectus-ny@ny.email.gs.com, or from BofA Merrill Lynch,
NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC
28255-0001, Attention: Prospectus Department, or by email to:
dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160823006265/en/
ACADIA Pharmaceuticals Inc.Lisa Barthelemy, Senior Director,
Investor Relations(858) 558-2871
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2024 to May 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From May 2023 to May 2024